James E Sidaway
Overview
Explore the profile of James E Sidaway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coltman N, Roberts R, Sidaway J
Exp Biol Med (Maywood)
. 2023 Dec;
248(21):1993-2000.
PMID: 38062553
Early de-risking of drug targets and chemistry is essential to provide drug projects with the best chance of success. Target safety assessments (TSAs) use target biology, gene and protein expression...
2.
Sidaway J, Orton T, Kalaitzi K, Jones H, Foster A, Lake B
Toxicology
. 2019 Dec;
430:152343.
PMID: 31836555
In this study liver tumours produced in male and female mice of the low spontaneous liver tumour incidence C57BL/10J strain treated for 99 weeks with 1000 ppm in the diet...
3.
Martin G, Kolida S, Marchesi J, Want E, Sidaway J, Swann J
Front Microbiol
. 2018 Jun;
9:1153.
PMID: 29922256
Bile acids, the products of concerted host and gut bacterial metabolism, have important signaling functions within the mammalian metabolic system and a key role in digestion. Given the complexity of...
4.
Wilkinson E, Sidaway J, Cross M
J Cell Physiol
. 2017 Jun;
233(1):186-200.
PMID: 28639275
The MEKK3/MEK5/ERK5 signaling axis is required for cardiovascular development in vivo. We analyzed the physiological role of ERK5 in cardiac endothelial cells and the consequence of activation of this kinase...
5.
Carr D, Ayehunie S, Davies A, Duckworth C, French S, Hall N, et al.
Pharmacol Ther
. 2017 Jan;
172:181-194.
PMID: 28132905
Adverse drug reactions affecting the gastrointestinal (GI) tract are a serious burden on patients, healthcare providers and the pharmaceutical industry. GI toxicity encompasses a range of pathologies in different parts...
6.
Wilkinson E, Sidaway J, Cross M
Biol Open
. 2016 Aug;
5(10):1362-1370.
PMID: 27543060
Cardiotoxicity induced by anti-cancer therapeutics is a severe, and potentially fatal, adverse reaction of the heart in response to certain drugs. Current in vitro approaches to assess cardiotoxicity have focused...
7.
Ravenscroft S, Pointon A, Williams A, Cross M, Sidaway J
Toxicol Sci
. 2016 Apr;
152(1):99-112.
PMID: 27125969
The immature phenotype of stem cell derived cardiomyocytes is a significant barrier to their use in translational medicine and pre-clinical in vitro drug toxicity and pharmacological analysis. Here we have...
8.
Gan X, Ettinger G, Huang C, Burton J, Haist J, Rajapurohitam V, et al.
Circ Heart Fail
. 2014 Mar;
7(3):491-9.
PMID: 24625365
Background: Probiotics are extensively used to promote gastrointestinal health, and emerging evidence suggests that their beneficial properties can extend beyond the local environment of the gut. Here, we determined whether...
9.
Armstrong D, Summers C, Ewart L, Nylander S, Sidaway J, van Giezen J
J Cardiovasc Pharmacol Ther
. 2014 Jan;
19(2):209-19.
PMID: 24414167
Introduction: Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addition to its potent inhibition of the P2Y12 receptor, which may explain some of ticagrelor's clinical...
10.
Pointon A, Abi-Gerges N, Cross M, Sidaway J
Toxicol Sci
. 2013 Jan;
132(2):317-26.
PMID: 23315586
Morphological damage to cardiomyocytes or loss of viability (structural cardiotoxicity) is a common cause of attrition in preclinical and clinical drug development. Currently, no predictive in vitro approaches are available...